Biocon Reports Q1 FY27 Unaudited Results; Board Approves Financials
Biocon Limited's Board approved unaudited standalone and consolidated financial results for Q1 FY27 (ended June 30, 2026). Consolidated profit was ₹1,368 million on total income of ₹43,905 million. Standalone profit was ₹522 million on total income of ₹6,893 million. The Board recommended a final dividend of ₹0.50 per share.
Financial results are material information for investors, impacting stock valuation and investor decisions. The dividend announcement also has an impact.
The announcement reports financial results and board meeting outcomes without significant positive or negative news.
Biocon Limited announced the outcome of its Board Meeting held on August 05, 2026, where the unaudited financial results for the quarter ended June 30, 2026, were approved. The results, prepared in accordance with Indian Accounting Standards (Ind-AS), encompass both standalone and consolidated financial statements.
The Board Meeting commenced at 2:30 p.m. and concluded at 3:34 p.m. The detailed financial results, along with the limited review report from the statutory auditors, have been enclosed and will also be available on the company's website, www.biocon.com.
For the quarter ended June 30, 2026, Biocon reported consolidated total income of ₹43,905 million and a profit for the period of ₹1,368 million. The consolidated total comprehensive income stood at ₹9,256 million. On a standalone basis, the company reported total income of ₹6,893 million and a net profit of ₹522 million for the same period, with a total comprehensive income of ₹638 million.
The company also provided segment-wise details for the consolidated results. The Biopharmaceuticals segment, comprising Biosimilars and Generics, generated ₹43,513 million in revenue. Within this, Biosimilars contributed ₹28,556 million, and Generics contributed ₹7,597 million. The Services segment reported revenue of ₹7,360 million.
Key events mentioned in the notes include the recommended final dividend of ₹0.50 per equity share by the Board of Directors on May 07, 2026, subject to shareholder approval at the Annual General Meeting. Additionally, Syngene International Limited recommended a final dividend of ₹1.25 per equity share on April 29, 2026, subject to shareholder approval at its Annual General Meeting.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.